Study Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? yes
Study Documents
Plain Language Summary Study Protocol Statistical Analysis PlanStudy Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? yes
Completed
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Beigene Study ID
ClinicalTrials.gov ID
EudraCT Number
China Drug Trials ID
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? yes
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? yes